8 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Showing 8 of 8 clinical reviews.
A detailed breakdown of the enrollment biases, attrition problems, generalizability gaps, statistical caveats, and conflict-of-interest concerns in the landmark Olsen finasteride 5-year hair-loss study.
A detailed methodology breakdown of the Olsen et al. 2002 finasteride 1 mg trial, examining randomization design, endpoint definitions, statistical approach, and how each choice shapes interpretation of 5-year AGA hair count data.
Deep-dive into the Olsen 2002 finasteride 5-year extension study: durability of hair count gains, regression patterns after discontinuation, long-term safety signals, and clinical implications for AGA treatment planning.
A deep dive into the primary and secondary endpoint results from the Olsen et al. 5-year finasteride 1 mg trial for androgenetic alopecia, including hair count trajectories, response distributions, and vertex vs frontal data.
A deep-dive into the pre-specified and post-hoc subgroup analyses from the Olsen et al. 5-year finasteride 1 mg trial, examining response differences by age, vertex vs frontal location, baseline hair count, and other clinical variables.
A deep-dive into the landmark 5-year finasteride 1 mg trial for androgenetic alopecia, covering methodology, results, limitations, and clinical relevance.
A deep-dive into the economic modeling, cost-per-QALY estimates, payer-coverage realities, and individual relative-value calculations derived from the Olsen et al. 2002 five-year finasteride trial in androgenetic alopecia.
How the Olsen 2002 five-year finasteride trial reshaped prescribing for androgenetic alopecia, which guidelines it influenced, and what it means for patients outside the original study population.